Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
zuma-12 save search
Philips proposes to re-appoint Chairman Feike Sijbesma and Peter Löscher and nominates Benoît Ribadeau-Dumas as member of the Supervisory Board
Published: 2024-02-20 (Crawled : 08:00) - globenewswire.com
GIC | $40.96 -0.82% 0.0% 57K
|
Retail Trade
|
| O: -0.64%
H: 0.2%
C: -0.63%
PHG | News | $20.97 -0.19% 0.0% 650K
|
Health Technology
|
| O: -0.94%
H: 0.55%
C: 0.2%
Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Published: 2023-02-09 (Crawled : 13:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.19%
H: 0.9%
C: -0.35%
tecartus t-cell leukemia trial therapy
Three-Year Follow-Up Analysis of Kite’s Yescarta® CAR T-cell Therapy (ZUMA-5 Trial) - 52% of Patients With Indolent Lymphomas Continued to Have Ongoing Responses at a Median Follow-Up of 40.5 Months
Published: 2022-12-12 (Crawled : 19:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.14%
H: 0.81%
C: 0.79%
yescarta ongoing lymphomas t-cell therapy
Yescarta® ZUMA-12 Study Demonstrates 78% Complete Response Rate as Part of First-Line Treatment in Newly Diagnosed High-Risk Large B-Cell Lymphoma
Published: 2021-12-13 (Crawled : 22:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: 0.0%
zuma-12 yescarta treatment risk t-cell
Humanigen Reports Positive Data With Lenzilumab in the ZUMA-19 CAR-T Phase 1b Study in DLBCL and Plans to Initiate a Potential Registrational Study
Published: 2021-04-19 (Crawled : 12:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: -0.96%
H: 0.0%
C: -4.79%
phase 1 potential positive car-t lenzilumab phase 1b phase 2b
U.S. Global Jets ETF (JETS) Surpassed $4 Billion in Assets Under Management (AUM) as Commercial Flight Demand Hit a 12-Month High
Published: 2021-03-18 (Crawled : 13:00) - globenewswire.com
GROW 4 | $2.68 2.92% 6.9K
|
Finance
|
| O: -0.63%
H: 1.78%
C: -1.78%
commercialization
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.